Mohammad H. Ghalib - Concepedia

Author

Mohammad H. Ghalib

Albert Einstein College of Medicine

Also Known As

M. H. Ghalib, M.H. Ghalib, Mohammad Ghalib, Mohammad H. Ghalib, Mohammad Haroon Ghalib

Publications

428

Citations

H-Index

Concepts

All Affiliations

Albert Einstein College of Medicine Montefiore Medical Center Oncolytics Biotech (Canada)

About

Mohammad H. Ghalib is an author at Albert Einstein College of Medicine specializing in radiation oncology, medicine, and oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	4	4	196
2	Pharmacology	3	3	46
3	Pathology	2	2	160
4	Cell Biology	1	1	11
5	Immunology	1	1	10

Mohammad H. Ghalib

Publications

228

Citations

H-Index

Page 1

	Year	Citations
Intravenous administration of Reolysin®, a live replication competent RNA virus is safe in patients with advanced solid tumors R. Gollamudi, Mohammad H. Ghalib, Kavita Desai, Investigational New Drugs Viral ReplicationMolecular VirologyIntravenous AdministrationMedicinePathology	2009	150
Elucidation of Pelareorep Pharmacodynamics in A Phase I Trial in Patients with <i>KRAS</i> -Mutated Colorectal Cancer Sanjay Goel, Allyson J. Ocean, Ruwan Y. Parakrama, Molecular Cancer Therapeutics	2020	32
A phase 1 open-label, sequential dose-escalation study investigating the safety, tolerability, and pharmacokinetics of intravenous TLC388 administered to patients with advanced solid tumors Sharad Ghamande, Chia‐Chi Lin, Daniel C. Cho, Investigational New Drugs Therapeutic Drug MonitoringMedicineMetronomic TherapyPharmacologySequential Dose-escalation Study	2013	25
Phase I study of ON 01910.Na, a novel polo-like kinase 1 pathway modulator, administered as a weekly 24-hour continuous infusion in patients with advanced cancer Jeffrey M. Vainshtein, Mohammad H. Ghalib, Mayank Kumar, Journal of Clinical Oncology On 01910.NaPharmacotherapyTumor BiologyPre-clinical PharmacologyOncology	2008	11
A multicenter phase I study of intravenous administration of reolysin in combination with irinotecan/fluorouracil/leucovorin (FOLFIRI) in patients (pts) with oxaliplatin-refractory/intolerant <i>KRAS-</i>mutant metastatic colorectal cancer (mCRC). Allyson J. Ocean, Tanios Bekaii‐Saab, Imran Chaudhary, Journal of Clinical Oncology Intravenous AdministrationViral PathogenesisImmunologyPathologyStrain Reovirus	2013	10

Page 1